241 related articles for article (PubMed ID: 36341432)
1. Antibody based conditioning for allogeneic hematopoietic stem cell transplantation.
Saha A; Blazar BR
Front Immunol; 2022; 13():1031334. PubMed ID: 36341432
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.
Saha A; Hyzy S; Lamothe T; Hammond K; Clark N; Lanieri L; Bhattarai P; Palchaudhuri R; Gillard GO; Proctor J; Riddle MJ; Panoskaltsis-Mortari A; MacMillan ML; Wagner JE; Kiem HP; Olson LM; Blazar BR
Blood; 2022 Mar; 139(11):1743-1759. PubMed ID: 34986233
[TBL] [Abstract][Full Text] [Related]
4. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
5. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
[TBL] [Abstract][Full Text] [Related]
7. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
Maris M; Storb R
Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197
[TBL] [Abstract][Full Text] [Related]
8. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Georges GE; Storb R
Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
11. Non-genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.
Chan YY; Ho PY; Swartzrock L; Rayburn M; Nofal R; Thongthip S; Weinberg KI; Czechowicz A
Transplant Cell Ther; 2023 Mar; 29(3):164.e1-164.e9. PubMed ID: 35995393
[TBL] [Abstract][Full Text] [Related]
12. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
14. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
15. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
Straathof KC; Rao K; Eyrich M; Hale G; Bird P; Berrie E; Brown L; Adams S; Schlegel PG; Goulden N; Gaspar HB; Gennery AR; Landais P; Davies EG; Brenner MK; Veys PA; Amrolia PJ
Lancet; 2009 Sep; 374(9693):912-20. PubMed ID: 19729196
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
[TBL] [Abstract][Full Text] [Related]
17. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
18. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.
Maris M; Storb R
Immunol Res; 2003; 28(1):13-24. PubMed ID: 12947221
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
20. Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.
Guo Z; Gao HY; Zhang TY; Liu XD; Yang K; Lou JX; He XP; Zhang Y; Chen P; Chen HR
Int J Hematol; 2016 Dec; 104(6):720-728. PubMed ID: 27709450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
